The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Statement 3.3
“Before making a pharmacy preparation, the hospital pharmacist must undertake a risk assessment to determine the best practice quality requirements. These must consider premises, equipment, pharmaceutical knowledge and labelling.”
What does it mean for patients? If the risk/benefit assessment is positive the pharmacist should decide about the necessary level of interventions necessary to optimize the quality of the produced medicine. Unambiguous and complete labelling is paramount to avoid any confusion, misinterpretation or administration error in the whole process.
What does it mean for healthcare professionals? Doctors and nurses should rely on the pharmacist as the expert in deciding about the necessary level of interventions necessary to optimize the quality of the produced medicine. Unambiguous and complete labelling is paramount to avoid any confusion, misinterpretation or administration error in the whole process.
What does it mean for Hospital Pharmacists? Patients have the right to get the best quality of medicines independently from industrial production or individual preparation. Hospital pharmacists should guarantee that
|
Premises, facilities and pharmaceutical knowledge should be appropriate for the preparation of the medicinal product and correct labelling should be assured through the whole process from production to administration.
- QUANTIFICATION OF WAITING TIME REDUCTION IN OUTPATIENT SETTING USING ASSISTED SYSTEMS IN AN AUTOMATED ONCOLOGY PHARMACY.
- OPTIMIZATION OF RISK MANAGEMENT OF DRUGS COLD CHAIN IN HOSPITAL BY FAILURE MODES, EFFECTS AND CRITICALITY ANALYSIS "FMECA" METHOD
- IMPLEMENTING A NATIONAL PORTFOLIO OF EXTEMPORANEOUS PHARMACEUTICAL PREPARATIONS USED IN DANISH HOSPITALS
- DEVELOPMENT OF NEW PRODUCTION WHEN NEITHER PACKAGING NOR SOME OF THE RAW MATERIALS CONFORM TO EUROPEAN STANDARDS
- HOW TO HANDLE ACTIVE AND PLACEBO DRUGS FOR A CLINICAL TRIAL IN THE PRODUCTION SYSTEM CATO IN ORDER TO SECURE THE BLIND AND TO ENSURE THE EXACT SAME PREPARATION OF ACTIVE AND PLACEBO PRODUCTS
- Resolution CM/Res(2016) on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients
- EJHP: Legislation on the preparation of medicinal products in European pharmacies and the Council of Europe Resolution
- EAHP Survey results 2016/2017 (sections 1,3 and 4)
- EAHP Survey Report 2015
- GPI:Implementing chemotherapy dose-banding using retrospective data analysis and exponential calculus
- EAHP Brochure